{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:17:50Z","timestamp":1790720270182,"version":"4.1.0"},"reference-count":104,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.5582\/bst.2026.01094","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:09:37Z","timestamp":1776377377000},"page":"301-310","source":"Crossref","is-referenced-by-count":1,"title":["Liver transplantation in Japan: Achievements, limitations, and future perspectives"],"prefix":"10.5582","volume":"20","author":[{"given":"Yasuhiko","family":"Sugawara","sequence":"first","affiliation":[{"name":"Department of Transplantation\/Pediatric Surgery, Postgraduate School of Life Science, Kumamoto University, Kumamoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014; 14:181-194.","DOI":"10.1038\/nri3623"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371:838-851.","DOI":"10.1016\/S0140-6736(08)60383-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gin\u00e8s P, Krag A, Abraldes JG, <i>et al<\/i>. Liver cirrhosis. Lancet. 2021; 398:1359-1376.","DOI":"10.1016\/S0140-6736(21)01374-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Terrault NA, Francoz C, Berenguer M, <i>et al<\/i>. Liver transplantation 2023: Status report, current and future challenges. Clin Gastroenterol Hepatol. 2023; 21:2150-2166.","DOI":"10.1016\/j.cgh.2023.04.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Umeshita K, Eguchi S, Egawa H, Haga H, Kasahara M, Kokudo N, Sakisaka S, Takada Y, Tanaka E, Eguchi H, Uemoto S, Ohdan H. Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society. Hepatol Res 2019; 49:964-980.","DOI":"10.1111\/hepr.13364"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Starzl TE, Brettschneider L, Penn I, <i>et al<\/i>. Orthotopic liver transplantation in man. Transplant Proc 1969; 1:216-222.","DOI":"10.1111\/j.1600-065X.1969.tb00206.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S; Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: The 5-5-500 rule - A retrospective study. Transpl Int. 2019; 32:356-368.","DOI":"10.1111\/tri.13391"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 2015; 62:158-165.","DOI":"10.1002\/hep.27787"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Duda DG, Dima SO, Cucu D, <i>et al<\/i>. Potential circulating biomarkers of recurrence after hepatic resection or liver transplantation in hepatocellular carcinoma patients. Cancers (Basel). 2020; 12.","DOI":"10.3390\/cancers12051275"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chaiteerakij R, Zhang X, Addissie, <i>et al<\/i>. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015; 21: 599-606.","DOI":"10.1002\/lt.24117"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009; 9:2362-71.","DOI":"10.1111\/j.1600-6143.2009.02783.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma.&quot; Review article. Ann Hepatol. 2021; 22:100249.","DOI":"10.1016\/j.aohep.2020.08.067"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. A Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of circulating tumor cells and their Implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021; 73:422-436.","DOI":"10.1002\/hep.31165"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. De Stefano N, Patrono D, Colli F, Rizza G, Paraluppi G, Romagnoli R. Liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors. Cancers (Basel). 2024; 16:237.","DOI":"10.3390\/cancers16132374"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, N\u00e4geli M, Mangana J, M\u00fcllhaupt B, Jenni F, Misselwitz B. Liver allograft failure after nivolumab treatment-A case report with systematic literature research. Transplant Direct. 2018; 4:e376.","DOI":"10.1097\/TXD.0000000000000814"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Martin SP, Mehta N, Emamaullee J. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities. Liver Transpl. 2024; 30:742-752.","DOI":"10.1097\/LVT.0000000000000350"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Marino R, Hassan AT, Fagenson A, Tabrizian P. Liver transplantation for hepatocellular carcinoma following immunotherapy. Curr Opin Organ Transplant. 2025; 30:242-250.","DOI":"10.1097\/MOT.0000000000001228"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64:73-84.","DOI":"10.1002\/hep.28431"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, Deshpande A, Ye W, Adekunle OA, McCullough A, Rothberg MB. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025; 8:e2454707.","DOI":"10.1001\/jamanetworkopen.2024.54707"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zarrinpar A, Busuttil RW. Liver transplantation: Past, present and future. Nat Rev Gastroenterol Hepatol. 2013; 10:434-440.","DOI":"10.1038\/nrgastro.2013.88"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Muthukrishnan S, Zhou J, Wang R, Bohlen J, Meier R, Shetty K, Bhati C. Challenges and strategies for optimizing liver transplantation outcomes in morbidly obese cirrhotic patients: A narrative review. BMC Surg. 2025; 25:267.","DOI":"10.1186\/s12893-025-02886-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67:1265-1273.","DOI":"10.1016\/j.jhep.2017.07.027"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Moctezuma-Velazquez C, M\u00e1rquez-Guill\u00e9n E, Torre A. Obesity in the liver transplant setting. Nutrients. 2019; 11:2552.","DOI":"10.3390\/nu11112552"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bambha KM, Dodge JL, Gralla J, Sprague D, Biggins SW. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: Risk modulated by model for end-stage liver disease. Liver Transpl. 2015; 21:1286-1294.","DOI":"10.1002\/lt.24188"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Alnimer L, Arellano D, Brombosz E, Noureddin M. Metabolic issues in patients with metabolic dysfunction-associated steatohepatitis (MASH) and their impact on MASH recurrence following liver transplantation: A narrative review. Liver Transpl. 2025; 31:1277-1285.","DOI":"10.1097\/LVT.0000000000000544"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Schlansky B, Naugler WE, Orloff SL, Enestvedt CK. Higher mortality and survival benefit in obese patients awaiting liver transplantation. Transplantation. 2016; 100:2648-2655.","DOI":"10.1097\/TP.0000000000001461"},{"key":"27","unstructured":"27. Halegoua-De Marzio DL, Wong SY, Fenkel JM, Doria C, Sass DA. Listing practices for morbidly obese patients at liver transplantation centers in the United States. Exp Clin Transplant. 2016; 14:646-649."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Are VS, Knapp SM, Banerjee A, Shamseddeen H, Ghabril M, Orman E, Patidar KR, Chalasani N, Desai AP. Improving outcomes of bariatric surgery in patients with cirrhosis in the United States: A nationwide assessment. Am J Gastroenterol. 2020; 115:1849-1856.","DOI":"10.14309\/ajg.0000000000000911"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Quezada N, Maturana G, Irarr\u00e1zaval MJ, Mu\u00f1oz R, Morales S, Achurra P, Az\u00f3car C, Crovari F. Bariatric surgery in cirrhotic patients: A matched case-control study. Obes Surg. 2020; 30:4724-4731.","DOI":"10.1007\/s11695-020-04929-y"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sharpton SR, Terrault NA, Posselt AM. Outcomes of sleeve gastrectomy in obese liver transplant candidates. Liver Transpl. 2019; 25:538-544.","DOI":"10.1002\/lt.25406"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Idriss R, Hasse J, Wu T, Khan F, Saracino G, McKenna G, Testa G, Trotter J, Klintmalm G, Asrani SK. Impact of prior bariatric surgery on perioperative liver transplant outcomes. Liver Transpl. 2019; 25:217-227.","DOI":"10.1002\/lt.25368"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005; 18:461-466.","DOI":"10.1111\/j.1432-2277.2004.00067.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Campsen J, Zimmerman M, Shoen J, Wachs M, Bak T, Mandell MS, Kam I. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg. 2008; 18:1625-1627.","DOI":"10.1007\/s11695-008-9633-5"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013; 13:363-368.","DOI":"10.1111\/j.1600-6143.2012.04318.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nesher E, Mor E, Shlomai A, Naftaly-Cohen M, Yemini R, Yussim A, Brown M, Keidar A. Simultaneous liver transplantation and sleeve gastrectomy: Prohibitive combination or a necessity? Obes Surg. 2017; 27:1387-1390.","DOI":"10.1007\/s11695-017-2634-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Zamora-Valdes D, Watt KD, Kellogg TA, Poterucha JJ, Di Cecco SR, Francisco-Ziller NM, Taner T, Rosen CB, Heimbach JK. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology. 2018; 68:485-495.","DOI":"10.1002\/hep.29848"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Gunturu NS, Castillo-Larios R, Bowers S, Edwards M, Burns J, Perry D, Elli EF. Combined sleeve gastrectomy with liver transplant in patients with obesity: A feasibility study. Obes Surg. 2022; 32:3600-3604.","DOI":"10.1007\/s11695-022-06289-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Al-Nowaylati AR, Al-Haddad BJ, Dorman RB, Alsaied OA, Lake JR, Chinnakotla S, Slusarek BM, Sampson BK, Ikramuddin S, Buchwald H, Leslie DB. Gastric bypass after liver transplantation. Liver Transpl. 2013; 19:1324-1329.","DOI":"10.1002\/lt.23734"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Lin MY, Tavakol MM, Sarin A, Amirkiai SM, Rogers SJ, Carter JT, Posselt AM. Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates. Surg Obes Relat Dis. 2013; 9:653-658.","DOI":"10.1016\/j.soard.2013.02.013"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Morris MC, Jung AD, Kim Y, Lee TC, Kaiser TE, Thompson JR, Bari K, Shah SA, Cohen RM, Schauer DP, Smith EP, Diwan TS. Delayed sleeve gastrectomy following liver transplantation: A 5-year experience. Liver Transpl. 2019; 25:1673-1681.","DOI":"10.1002\/lt.25637"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387:205-216.","DOI":"10.1056\/NEJMoa2206038"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022; 10:393-406.","DOI":"10.1016\/S2213-8587(22)00070-5"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Battistella S, D&apos;Arcangelo F, Grasso M, Zanetto A, Gambato M, Germani G, Senzolo M, Russo FP, Burra P. Liver transplantation for non-alcoholic fatty liver disease: Indications and post-transplant management. Clin Mol Hepatol. 2023; 29:S286-s301.","DOI":"10.3350\/cmh.2022.0392"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. Semaglutide <i>vs<\/i> endoscopic sleeve gastroplasty for weight loss. JAMA Netw Open. 2024; 7:e246221.","DOI":"10.1001\/jamanetworkopen.2024.6221"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol. 2022; 77:1161-1197.","DOI":"10.1016\/j.jhep.2022.07.008"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Shaheen AA, Kong K, Ma C, Doktorchik C, Coffin CS, Swain MG, Burak KW, Congly SE, Lee SS, Sadler M, Borman M, Abraldes JG. Impact of the COVID-19 pandemic on hospitalizations for alcoholic hepatitis or cirrhosis in Alberta, Canada. Clin Gastroenterol Hepatol. 2022; 20:e1170-e1179.","DOI":"10.1016\/j.cgh.2021.10.030"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Cholankeril G, Goli K, Rana A, Hernaez R, Podboy A, Jalal P, Da BL, Satapathy SK, Kim D, Ahmed A, Goss J, Kanwal F. Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA. Hepatology. 2021; 74:3316-3329.","DOI":"10.1002\/hep.32067"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Lee BP, Vittinghoff E, Dodge JL, Cullaro G, Terrault NA. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med. 2019; 179:340-348.","DOI":"10.1001\/jamainternmed.2018.6536"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Addolorato G, Bataller R, Burra P, DiMartini A, Graziadei I, Lucey MR, Mathurin P, O\u02bcGrady J, Pageaux G, Berenguer M. Liver transplantation for alcoholic liver disease. Transplantation. 2016; 100:981-987.","DOI":"10.1097\/TP.0000000000001156"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Vassallo GA, Tarli C, Rando MM, Mosoni C, Mirijello A, Agyei-Nkansah A, Antonelli M, Sestito L, Perotti G, Di Giuda D, Agnes S, Grieco A, Gasbarrini A, Addolorato G; Gemelli OLT Group. Liver transplantation in patients with alcoholic liver disease: A retrospective study. Alcohol Alcohol. 2018; 53:151-156.","DOI":"10.1093\/alcalc\/agx097"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Lim J, Kim SE, Jo AJ, <i>et al<\/i>. Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation. Hepatol Int. 2024; 18:1579-1588.","DOI":"10.1007\/s12072-024-10710-5"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Shenoy A, Salajegheh A, Shen NT. Multimodal multidisciplinary management of alcohol use disorder in liver transplant candidates and recipients. Transl Gastroenterol Hepatol. 2022; 7:28.","DOI":"10.21037\/tgh.2020.02.22"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duclos-Vall\u00e9e JC. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011; 365:1790-1800.","DOI":"10.1056\/NEJMoa1105703"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Wong E, Mullins PD, Wallach JP, Yoshida EM, Erb SR, Ford JA, Scudamore CH, Marquez V. Patients&apos; perspectives on early liver transplantation in alcohol-related liver disease. Hepatol Commun. 2019; 3:1022-1031.","DOI":"10.1002\/hep4.1390"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Louvet A, Labreuche J, Moreno C, <i>et al<\/i>. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: A prospective controlled study. Lancet Gastroenterol Hepatol. 2022; 7:416-425.","DOI":"10.1016\/S2468-1253(21)00430-1"},{"key":"56","unstructured":"56. Lee BP, Mehta N, Platt L, <i>et al<\/i>. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology. 2018; 155:422-430.e421."},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Thursz M, Allison M. Liver transplantation for alcoholic hepatitis: Being consistent about where to set the bar. Liver Transpl. 2018; 24:733-734.","DOI":"10.1002\/lt.25188"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Lee BP, Im GY, Rice JP, <i>et al<\/i>. Patterns of alcohol use after early liver transplantation for alcoholic hepatitis. Clin Gastroenterol Hepatol. 2022; 20:409-418.e405.","DOI":"10.1016\/j.cgh.2020.11.024"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Arab JP, D\u00edaz LA, Baeza N, <i>et al<\/i>. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021; 75:1026-1033.","DOI":"10.1016\/j.jhep.2021.06.019"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Musto J, Stanfield D, Ley D, Lucey MR, Eickhoff J, Rice JP. Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis. Hepatology. 2022; 75:104-114.","DOI":"10.1002\/hep.32110"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O&apos;Grady JG, Akriviadis E, Sinakos E, Carithers RL Jr, Ramond MJ, Maddrey WC, Morgan TR, Duhamel A, Mathurin P. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-A meta-analysis of individual data from controlled trials. Gastroenterology. 2018; 155:458-468.e458.","DOI":"10.1053\/j.gastro.2018.05.011"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Morales-Arr\u00e1ez D, Ventura-Cots M, Altamirano J, <i>et al<\/i>. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study. Am J Gastroenterol. 2022; 117:301-310.","DOI":"10.14309\/ajg.0000000000001596"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Germani G, Angrisani D, Addolorato G, <i>et al<\/i>. Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. Am J Transplant. 2022; 22:1191-1200.","DOI":"10.1111\/ajt.16936"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Lombardo-Quezada J, Colmenero J, L\u00f3pez-Pelayo H, Gavotti C, Lopez A, Crespo G, Lopez E, Gual A, Lligo\u00f1a A, Navasa M. Prediction of alcohol relapse among liver transplant candidates with less than 6 months of abstinence using the high-risk alcoholism relapse score. Liver Transpl. 2019; 25:1142-1154.","DOI":"10.1002\/lt.25460"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Deutsch-Link S, Weinrieb RM, Jones LS, Solga SF, Weinberg EM, Serper M. Prior relapse, ongoing alcohol consumption, and failure to engage in treatment predict alcohol relapse after liver transplantation. Dig Dis Sci. 2020; 65:2089-2103.","DOI":"10.1007\/s10620-019-05937-4"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Arab JP, Bataller R. Advancing alcohol-related liver disease: From novel biomarkers to refining selection for liver transplantation. Nat Rev Gastroenterol Hepatol. 2023; 20:71-72.","DOI":"10.1038\/s41575-022-00723-6"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Guo Z, Zhao Q, Huang S, <i>et al<\/i>. Ischaemia-free liver transplantation in humans: A first-in-human trial. Lancet Reg Health West Pac. 2021; 16:100260.","DOI":"10.1016\/j.lanwpc.2021.100260"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. L\u00f3pez-Mart\u00ednez S, Sim\u00f3n C, Santamaria X. Normothermic machine perfusion systems: Where do we go from here? Transplantation. 2024; 108:22-44.","DOI":"10.1097\/TP.0000000000004573"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Muller X, Schlegel A, Kron P, Eshmuminov D, W\u00fcrdinger M, Meierhofer D, Clavien PA, Dutkowski P. Novel real-time prediction of liver graft function during hypothermic oxygenated machine perfusion before liver transplantation. Ann Surg. 2019; 270:783-790.","DOI":"10.1097\/SLA.0000000000003513"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. van Rijn R, Schurink IJ, de Vries Y, <i>et al<\/i>. Hypothermic machine perfusion in liver transplantation - A randomized trial. N Engl J Med. 2021; 384:1391-1401.","DOI":"10.1056\/NEJMoa2031532"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Mazilescu LI, Selzner M, Selzner N. Defatting strategies in the current era of liver steatosis. JHEP Rep. 2021; 3:100265.","DOI":"10.1016\/j.jhepr.2021.100265"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Starzl TE, Fung J, Tzakis A, <i>et al<\/i>. Baboon-to-human liver transplantation. Lancet. 1993; 341:65-71.","DOI":"10.1016\/0140-6736(93)92553-6"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Cross-Najafi AA, Lopez K, Isidan A, Park Y, Zhang W, Li P, Yilmaz S, Akbulut S, Ekser B. Current barriers to clinical liver xenotransplantation. Front Immunol. 2022; 13:827535.","DOI":"10.3389\/fimmu.2022.827535"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Schmauch E, Piening B, Mohebnasab M, <i>et al<\/i>. Integrative multi-omics profiling in human decedents receiving pig heart xenografts. Nat Med. 2024; 30:1448-1460.","DOI":"10.1038\/s41591-024-02972-1"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Shah JA, Navarro-Alvarez N, DeFazio M, Rosales IA, Elias N, Yeh H, Colvin RB, Cosimi AB, Markmann JF, Hertl M, Sachs DH, Vagefi PA. A bridge to somewhere: 25-day survival after pig-to-baboon liver xenotransplantation. Ann Surg. 2016; 263:1069-1071.","DOI":"10.1097\/SLA.0000000000001659"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Shah JA, Patel MS, Elias N, Navarro-Alvarez N, Rosales I, Wilkinson RA, Louras NJ, Hertl M, Fishman JA, Colvin RB, Cosimi AB, Markmann JF, Sachs DH, Vagefi PA. Prolonged survival following pig-to-primate liver xenotransplantation utilizing exogenous coagulation factors and costimulation blockade. Am J Transplant. 2017; 17:2178-2185.","DOI":"10.1111\/ajt.14341"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Tao KS, Yang ZX, Zhang X, <i>et al<\/i>. Gene-modified pig-to-human liver xenotransplantation. Nature. 2025; 641:1029-1036.","DOI":"10.1038\/s41586-025-08799-1"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Zhang W, Xu Q, Xu K, <i>et al<\/i>. Genetically engineered pig-to-human liver xenotransplantation. J Hepatol. 2026; 84:587-598.","DOI":"10.1016\/j.jhep.2025.08.044"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Griffith BP, Goerlich CE, Singh AK, <i>et al<\/i>. Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med. 2022; 387:35-44.","DOI":"10.1056\/NEJMoa2201422"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Fishman JA, Scobie L, Takeuchi Y. Xenotransplantation-associated infectious risk: a WHO consultation. Xenotransplantation. 2012; 19:72-81.","DOI":"10.1111\/j.1399-3089.2012.00693.x"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Giovinazzo F, Pascale MM, Cardella F, Picarelli M, Molica S, Zotta F, Martullo A, Clarke G, Frongillo F, Grieco A, Agnes S. Current perspectives in liver transplantation for perihilar cholangiocarcinoma. Curr Oncol. 2023; 30:2942-2953.","DOI":"10.3390\/curroncol30030225"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Breuer E, Mueller M, Doyle MB, <i>et al<\/i>. Liver transplantation as a New Standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study. Ann Surg. 2022; 276:846-853.","DOI":"10.1097\/SLA.0000000000005641"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Sapisochin G, Facciuto M, Rubbia-Brandt L, <i>et al<\/i>. Liver transplantation for &quot;very early&quot; intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016; 64:1178-1188.","DOI":"10.1002\/hep.28744"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012; 56:972-981.","DOI":"10.1002\/hep.25629"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Ziogas IA, Hickman LA, Matsuoka LK, Izzy M, Montenovo MI, Rega SA, Feurer ID, Alexopoulos SP. Comparison of wait-list mortality between cholangiocarcinoma and hepatocellular carcinoma liver transplant candidates. Liver Transpl. 2020; 26:1112-1120.","DOI":"10.1002\/lt.25807"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Gringeri E, Furlanetto A, Billato I, <i>et al.<\/i> The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: A national survey and future perspectives. Updates Surg. 2024; 76:2505-2513.","DOI":"10.1007\/s13304-024-01889-1"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. De Martin E, Rayar M, Golse N, <i>et al<\/i>. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020; 26:785-798.","DOI":"10.1002\/lt.25737"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Lunsford KE, Javle M, Gaber AO, Vauthey JN, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma - Authors&apos; reply. Lancet Gastroenterol Hepatol. 2018; 3:529-530.","DOI":"10.1016\/S2468-1253(18)30167-5"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Maspero M, Rossi RE, Sposito C, Coppa J, Citterio D, Mazzaferro V. Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria. Am J Transplant. 2022; 22:2598-2607.","DOI":"10.1111\/ajt.17156"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Nguyen NT, Harring TR, Goss JA, O&apos;Mahony CA. Neuroendocrine liver metastases and orthotopic liver transplantation: The US experience. Int J Hepatol. 2011; 2011:742890.","DOI":"10.4061\/2011\/742890"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, W\u00e4ngberg B, Ahlman H. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007; 13:327-333.","DOI":"10.1002\/lt.21056"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, Camerini T, Milione M, Regalia E, Spreafico C, Gangeri L, Buzzoni R, de Braud FG, De Feo T, Mariani L. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016; 16:2892-2902.","DOI":"10.1111\/ajt.13831"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Lim C, Lahat E, Osseis M, Sotirov D, Salloum C, Azoulay D. Liver transplantation for neuroendocrine tumors: What have we learned? Semin Liver Dis. 2018; 38:351-356.","DOI":"10.1055\/s-0038-1669936"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Bosc\u00e0 A, Montalv\u00e1 EM, Vila-Tura M, <i>et al.<\/i> Should we continue liver transplantation in Spain for hepatic metastases from neuroendocrine tumors? J Clin Med. 2026; 15:938.","DOI":"10.3390\/jcm15030938"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015; 261:956-960.","DOI":"10.1097\/SLA.0000000000000786"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Rajendran L, Claasen MP, McGilvray ID, Cattral MS, Ghanekar A, Selzner N, Burkes R, Winter E, Gallinger S, Sapisochin G. Toronto management of initially unresectable liver metastasis from colorectal cancer in a living donor liver transplant program. J Am Coll Surg. 2023; 237:231-242.","DOI":"10.1097\/XCS.0000000000000734"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Hernandez-Alejandro R, Ruffolo LI, Sasaki K, <i>et al<\/i>. Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases. JAMA Surg. 2022; 157:524-530.","DOI":"10.1001\/jamasurg.2022.0300"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Nakao Y, Adam R, Nasser AH, <i>et al<\/i>. Two-stage hepatectomy versus liver transplantation for patients with marginally resectable extensive bilobar colorectal liver metastases. Ann Surg. 2026; 283:365-374.","DOI":"10.1097\/SLA.0000000000006904"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Becker F, Morg\u00fcl H, Katou S, Juratli M, H\u00f6lzen JP, Pascher A, Struecker B. Robotic liver surgery - Current standards and future perspectives. Z Gastroenterol. 2021; 59:56-62.","DOI":"10.1055\/a-1329-3067"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Broering DC, Raptis DA, Elsheikh Y. Pioneering fully robotic donor hepatectomy and robotic recipient liver graft implantation \u2013 A new horizon in liver transplantation. Int J Surg. 2024; 110:1333-1336.","DOI":"10.1097\/JS9.0000000000001031"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Khan AS, Scherer M, Panni R, Cullinan D, Martens G, Kangarga I, King CR, Benzinger R, Wellen JR, Chapman WC, Doyle MB. Total robotic liver transplant: The final frontier of minimally invasive surgery. Am J Transplant. 2024; 24:1467-1472.","DOI":"10.1016\/j.ajt.2024.03.030"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Pinto-Marques H, Sobral M, Magistri P, Gomes da Silva S, Guerrini GP, Mega R, Guidetti C, Coelho JS, Di Sandro S, Di Benedetto F. Full robotic whole graft liver transplantation: A step into the future. Ann Surg. 2025; 281:67-70.","DOI":"10.1097\/SLA.0000000000006420"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Lee KW, Choi Y, Hong SK, Lee S, Hong SY, Suh S, Han ES, Yi NJ, Suh KS. Laparoscopic donor and recipient hepatectomy followed by robot-assisted liver graft implantation in living donor liver transplantation. Am J Transplant. 2022; 22:1230-1235.","DOI":"10.1111\/ajt.16943"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Suh KS, Hong SK, Lee S, Hong SY, Suh S, Han ES, Yang SM, Choi Y, Yi NJ, Lee KW. Pure laparoscopic living donor liver transplantation: Dreams come true. Am J Transplant. 2022; 22:260-265.","DOI":"10.1111\/ajt.16782"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/3\/20_2026.01094\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:15:03Z","timestamp":1784348103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/3\/20_2026.01094\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01094","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"2026.01094"}}